Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen)

Human Vaccines

Volumn 7, Issue 5, 2011, Pages 563-568

  Dennehy, Penelope H ^a   Vesikari, Timo ^b   Matson, David O ^c   Itzler, Robbin F ^d   Dallas, Michael J ^d   Goveia, Michelle G ^d   DiNubile, Mark J ^d   Heaton, Penny M ^d,e   Ciarlet, Max ^d,e  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^c OLD DOMINION UNIVERSITY   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

3 Dose series; Between doses; Early protection; Efficacy; Health care encounters; Infant; Pentavalent vaccine; Rotavirus gastroenteritis; RV5

Indexed keywords

PLACEBO; ROTAVIRUS VACCINE;

ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; GASTROENTERITIS; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS INFECTION; SEROTYPE; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION;

GASTROENTERITIS; HOSPITALIZATION; HUMANS; IMMUNIZATION, SECONDARY; INFANT; PLACEBOS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED;

EID: 79955944472     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.5.15406     Document Type: Article

References (21)

1. Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2009; 58:2.
2. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, et al. Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine in preventing rotavirus gastroenteritis and reducing associated healthcare resource utilization. N Engl J Med 2006; 354:23-33.
3. Ciarlet M, Schödel F. The path to rotavirus vaccine development and the clinical data supporting safety, immunogenicity and efficacy of the pentavalent rotavirus vaccine, RotaTeq. Vaccine 2009; 27:72-81.
4. Parashar UD, Alexander JP, Glass RI. Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2006; 55:1-13.
5. Forster J, Guarino A, Parez N, Moraga F, Román E, Mory O, et al. Hospital-based surveillance to estimate the burden of rotavirus gastroenteritis among European children younger than 5 years of age. Pediatrics 2009; 123:393-400.
6. Van Damme P, Giaquinto C, Huet F, Gothefors L, Maxwell M, Van der Wielen M. REVEAL Study Group. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe 2004-2005: the REVEAL study. J Infect Dis 2007; 195:4-16.
7. Mészner Z, Balogh A, Bányai K, Kovács J, Pazdiora P, Mrukowicz J, et al. The clinical burden of rotavirus disease: retrospective analysis of infant and childhood gastroenteritis in seven countries in Central and eastern Europe. Pediatr Infect Dis J 2008; 27:33-41.
8. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomized, double-blind controlled study. Lancet 2007; 370:1757-63. (Pubitemid 350137490)
9. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Record of the Proceedings. June 25-26, 2008; Atlanta GA.
10. Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, Gentsch JR, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010; 125:199-207.
11. th International Conference on vaccines for Enteric Diseases (VED); September 9-11, 2009; Málaga, Spain.
12. Centers for Disease Control and Prevention. Delayed onset and diminished magnitude of rotavirus activity - United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008; 57:697-700.
13. Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010; 125:208-13.
14. Patel MM, Steele D, Gentsch JR, Wecker J, Glass RI, Parashar UD. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 2011; 30:1-5.
15. Lambert SB, Faux CE, Hall L, Birrell FA, Peterson KV, Selvey CE, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Aust 2009; 191:157-60.
16. Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009; 301:2243-51.
17. Gagneur A, Lemaitre T, Nowak E, Segura JF, Delaperriere N, Abalea L, et al. Impact of a vaccination campaign in infants (nourrissions) on hospitalizations for acute rotavirus diarrhea in France: the Ivanhoe study. Abstract presented at: 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 4-8, 2010; Nice, France.
18. th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 4-8, 2010; Nice, France.
19. th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 4-8, 2010; Nice, France.
20. Heaton PM, Ciarlet M. The pentavalent rotavirus vaccine: discovery to licensure and beyond. Clin Infect Dis 2007; 45:1618-24. (Pubitemid 351411848)
21. Jovanovic BD, Zalenski RJ. Safety evaluation and confidence intervals when the number of observed events is small or zero. Ann Emerg Med 1997; 30:301-6. (Pubitemid 27371871)